Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Zhong J, Li L, Wang Z, Bai H, Gai F, Duan J, Zhao J, Zhuo M, Wang Y, Wang S, Zang W, Wu M, An T, Rao G, Zhu G, Wang J. Zhong J, et al. Among authors: gai f. J Thorac Oncol. 2017 Dec;12(12):1766-1778. doi: 10.1016/j.jtho.2017.07.032. Epub 2017 Aug 14. J Thorac Oncol. 2017. PMID: 28818608 Free article.
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H, Yang X, Li K, Wang J, Lv J, Li X, Zhang X, Qin N, Zhang Q, Wu Y, Ma L, Gai F, Hu Y, Zhang S. Zhang H, et al. Among authors: gai f. Zhongguo Fei Ai Za Zhi. 2021 Feb 20;24(2):78-87. doi: 10.3779/j.issn.1009-3419.2021.104.02. Epub 2021 Jan 22. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33478196 Free PMC article. Chinese.
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Han X, Tang X, Zhu H, Zhu D, Zhang X, Meng X, Hua Y, Wang Z, Zhang Y, Huang W, Wang L, Yuan S, Zhang P, Gong H, Sun Y, Zhang Y, Liu Z, Dong X, Gai F, Huang Z, Zhu C, Guo J, Wang Z. Han X, et al. Among authors: gai f. J Immunother Cancer. 2022 Dec;10(12):e004952. doi: 10.1136/jitc-2022-004952. J Immunother Cancer. 2022. PMID: 36600554 Free PMC article. Clinical Trial.
277 results